Dongbang FTL

Dongbang FTL is a South Korean pharmaceutical company specializing in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and intermediate chemicals. Established in 1990, the company has built a robust reputation for high-quality synthesis and large-scale production, serving both domestic and international markets. Notably, Dongbang FTL was selected by the Medicines Patent Pool (MPP) to manufacture generic versions of Pfizer's COVID-19 oral treatment, nirmatrelvir, and MSD's molnupiravir for low- and middle-income countries. The company operates state-of-the-art manufacturing facilities that comply with international standards, including KGMP and BGMP. Their product portfolio spans various therapeutic areas, including antivirals, cardiovascular agents, and metabolic disorders.